FDA approves first cartilage implant for osteoarthritis

Screen-Shot-2015-05-11-at-6.56.07-AMCartiva has won an FDA premarket approval for its cartilage implant to treat osteoarthritis at the base of the big toe. It is the first synthetic cartilage implant approved by the FDA.

The Synthetic Cartilage Implant (SCI) is an alternative to standard of care: fusing the bones in the foot with screws and plates. While this effectively takes care of pain from the arthritic joint, it also permanently stops it from moving.

A biocompatible, biomedical polymer implant designed to mimic the physical characteristics of articular cartilage, the implant replaces damaged cartilage, relieving pain while maintaining joint function. The procedure takes about 35 minutes and, unlike fusion, allows patients to immediately put as much weight as they can tolerate on the foot.


About Peter Coffaro 1149 Articles

A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the medical device industry. As a District Sales Manager for Stryker Orthopaedics, Peter was responsible for managing and directing a regional sales force to achieve sales and profit goals within the Rocky Mountain region. Previously, he was the Director of Sales & Marketing for Amp Orthopedics. In this role, Peter was responsible for planning, developing, and leading all sales and marketing initiatives. Peter is a former orthopedic distributor in the Pacific Northwest. He has also worked with DePuy Orthopaedics as well as Zimmer, and held positions in sales, sales training, and sales management. Peter has an extensive background in organizational development, business development, sales management, negotiating and P&L management. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.